Moderate to severe atopic dermatitis in patients ≥6 yr inadequately controlled w/ topical prescription therapies or when those therapies are not advisable, can be used w/ or w/o topical corticosteroids. Add-on maintenance treatment for severe asthma w/ type 2 inflammation in adults & adolescents ≥12 yr. Maintenance therapy for oral corticosteroid-dependent asthma.
SCAtopic dermatitisAdult, adolescent & ped 6-17 yr, ≥60 kg Initially 600 mg, followed by 300 mg every other wk. Ped 6-17 yr, 30 to <60 kg Initially 400 mg, followed by 200 mg every other wk, 15 to <30 kg Initially 600 mg, followed by 300 mg every 4 wk. Adult & adolescent ≥12 yr Asthma Initially 400 mg, followed by 200 mg every other wk. Severe asthma, patient who are on oral corticosteroids or w/ severe asthma & comorbid moderate to severe atopic dermatitis or severe chronic rhinosinusitis w/ nasal polyposis Initially 600 mg, followed by 300 mg every other wk.
Discontinue use if hypersensitivity reaction occurs. Not to be inj into tender, damaged, bruised or scarred skin. Not to be used for acute asthma symptoms or exacerbations; acute bronchospasm or status asthmaticus. Conjunctivitis, keratitis; comorbid asthma; parasitic helminth infections; vasculitic rash, worsened pulmonary symptoms, cardiac complications &/or neuropathy presenting in patients w/ eosinophilia. Immunogenicity. Avoid abrupt discontinuation of systemic, topical or inhaled corticosteroids. Pregnancy & lactation. Ped patients <6 yr.
Sign Out
